PT - JOURNAL ARTICLE AU - Kevin M. Maloney AU - Adrien Le Guillou AU - Robert A. Driggers AU - Supriya Sarkar AU - Emeli J. Anderson AU - Amyn A. Malik AU - Samuel M. Jenness TI - Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral HIV Pre-Exposure Prophylaxis: A Mathematical Model AID - 10.1101/19012443 DP - 2020 Jan 01 TA - medRxiv PG - 19012443 4099 - http://medrxiv.org/content/early/2020/08/12/19012443.short 4100 - http://medrxiv.org/content/early/2020/08/12/19012443.full AB - Background Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) is reportedly efficacious, although full trial results have not been published. We used a dynamic network model of HIV transmission among men who have sex with men (MSM) to assess the population impact of LAI-PrEP when available concurrently with daily-oral (DO) PrEP.Methods The reference model represents the current HIV epidemiology and DO-PrEP coverage (15% among indicated) among MSM in the southeastern US. Primary analyses investigated varied PrEP uptake and proportion selecting LAI-PrEP. Secondary analyses evaluated uncertainty in pharmacokinetic efficacy and LAI-PrEP persistence relative to DO-PrEP.Results Compared to the reference scenario, if 50% chose LAI-PrEP, 4.3% (95% SI: −7.3%, 14.5%) of infections would be averted over 10 years. LAI-PrEP impact is slightly greater than the DO-PrEP only regimen based on assumptions of higher adherence and partial protection after discontinuation. If the total PrEP initiation rate doubled, 17.1% (95% SI: 6.7%, 26.4%) of infections would be averted. The highest population-level impact occurred when LAI-PrEP uptake and persistence improved.Conclusions If LAI-PrEP replaces DO-PrEP, its availability will modestly improve the population impact. LAI-PrEP will make a more substantial impact if its availability drives higher total PrEP coverage, or if persistence is greater for LAI-PrEP.Summary Long-acting injectable pre-exposure prophylaxis (LAI-PrEP) will modestly decrease HIV incidence if it replaces daily-oral PrEP use among men who have sex with men. LAI-PrEP will make a more substantial impact if its availability drives higher total PrEP coverage.Competing Interest StatementS.S. is an employee of ViiV Healthcare, which owns the patent for cabotegravir.Funding StatementThis work was supported by National Institutes of Health grants R21 MH112449, R01 AI138783, and P30 AI050409 (Emory University Center for AIDS Research).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis work was a simulation of disease transmission and does not represent analysis of primary data. The simulation parameters were derived from a variety of published data sources and referenced throughout the manuscript as necessary. https://github.com/EpiModel/injectable-prep